T he US President's Council of Advisors on Science and Technology (PCAST) has rarely fulfilled the full potential of its nominal role, which is to provide the most powerful elected official in the world with scientific advice.
In theory, the presidentially appointed panel could keep the president informed on key science-and technology-related issues, ranging from avian flu and global warming to computer viruses and nuclear-weapons proliferation.
In practice, however, the panel has never lived up to that ideal. It came closest, perhaps, under the first President Bush, who graced PCAST meetings with his presence. The panel was active but not particularly influential under Bill Clinton, and has been almost invisible under the current president.
So the news that PCAST is to be merged with another, even more obscure panel, the President's Information Technology Advisory Committee (PITAC), will make few waves. Nonetheless, the amalgamation of the panels, and the expansion of the possible number of members from 25 to an unwieldy 45, portends a possible weakening of the voice of science in the White House.
PCAST has already confined itself to the relative arcana of science policy. At the moment, for example, it is evaluating the effectiveness of the National Nanotechnology Initiative -a worthwhile exercise, but hardly one that is likely to grab the president's attention.
Floyd Kvamme, a venture capitalist who co-chairs PCAST with John Marburger, the president's science adviser, says the new panel will operate much as before, with the new work delegated to appropriate subcommittees. But unless the panel becomes considerably more active, its new role overseeing all the information-technology research initiatives in the federal government may mean that less time and resources are available to work on science issues. This marks a continuation of the tendency of the Bush administration to marginalize the voices of science in its internal deliberations.
One of the difficulties that will always face a body such as PCAST is the sheer vastness of the territory it is supposed to cover. These days, advice on specific scientific questions will often require detailed specializations that few PCAST members will possess. At the same time, there is a tendency for officially designated advisory bodies that are required by US law to meet in public -such as PCAST -to shun robust discussion of substantive issues. Finally, the president's discretion in appointing the entire panel himself is not conducive to the delivery of solid and occasionally unwelcome advice.
PCAST is the latest in a series of similar panels stretching back to the administration of Harry Truman. Some have been more active and influential than others, depending largely on the president's own interest in science and his relationship with the chief science adviser. Perhaps a future administration will develop the committee's role and profile instead of neglecting it -but even then, the panel's preeminence will last only as long at that president's term in office. ■ (including the United States) have pledged a total of just $16.5 million. The outbreak teams of the World Health Organization (WHO) are dwarfed by the challenge facing them.
Many scientists in affected countries are reluctant to cooperate with what often seems to them a one-way street. Hospitals in these countries often have barely enough antivirals to treat existing cases, and lack diagnostics. A better atmosphere for sharing will only come if rich nations offer these countries true cooperation and substantial aid in research and health infrastructure to deal with outbreaks.
US officials have in the past weeks made strident warnings about the lack of preparedness for a pandemic, while simultaneously giving overly reassuring messages that the job is now well in hand. Much of the $3.9 billion in the Senate bill would go towards buying drugs, for example. But US officials have neglected to mention that the United States currently has only enough drugs ordered to cover 1% of its population. Ten countries already have drugs ordered to cover 25-40% of their populations, but it will be several years before the United States can match this, as it is at the back of the queue at the door of Roche, the sole supplier of Tamiflu.
Roche's monopoly on the drug, and its inability to ramp up production swiftly to meet demand, are themselves cause for concern. UN secretary-general Kofi Annan last week hinted that countries might use compulsory licences to produce the drug off-patent, arguing that intellectual-property rights should not be allowed to get in the way of access by the poor to medication. This option has been rejected by the WHO, which recently obtained a donation of 3 million courses from Roche.
With few drugs on the horizon, US officials are stressing that the key weapon in the event of a pandemic will be a vaccine, and that the biggest bottleneck is in industry's capacity to produce it in sufficient quantities. But the vaccine in question is a prototype. It requires such huge doses that, even if the entire world vaccine production capacity of 900 million doses of seasonal flu vaccine antigen were switched to making it, just 75 million doses could be manufactured. In contrast, antigen-sparing strategies using adjuvants could allow from 1 billion to 7 billion doses to be produced, and this is why all efforts should be directed to this goal.
Although research into new vaccines and drugs may help us fight pandemics better several years down the line, the frontline of a pandemic would be in communities and hospitals, so this is where governments need to focus their disaster planning. For example, taps and door knobs in washrooms are a significant route of flu transmission. Converting them to be pushed or opened with an elbow, as in surgical areas of hospitals, could cut transmission during a pandemic.
Vaccines and antiviral drugs deserve top-level attention. But so too do much simpler means of protecting citizens.
■ "The frontline would be in communities and hospitals, so this is where governments need to focus their disaster planning." "The president's discretion in appointing the panel himself is not conducive to the delivery of solid or unwelcome advice."
